Vimal Mehta | Chief Executive Officer & Founder |
Matt Wiley | Chief Commercial Officer |
Richard Steinhart | Chief Financial Officer |
Rob Risinger | Chief Medical Officer, Neuroscience |
Vincent O’Neill | Chief R&D Officer of OnkosXcel Therapeutics |
Colin Bristow | UBS |
Robyn Karnauskas | Truist Securities |
Greg Harrison | Bank of America |
Graig Suvannavejh | Mizuho Securities |
Sumant Kulkarni | Canaccord Genuity |
Eddie Hickman | Guggenheim Partners |
Corinne Jenkins | Goldman Sachs |
Ram Selvaraju | H.C. Wainwright |
Samir Devani | Rx Securities |
Good morning, and welcome to the BioXcel Therapeutics Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions]
Just to remind everyone, certain matters discussed in today's conference call and/or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and/or the future financial or business performance of the company.
Actual results could differ materially from those anticipated in these forward-looking statements.